LOBO EV and Nexalin Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ACCESSWIRE · RedChip

In This Article:

ORLANDO, FL / ACCESSWIRE / July 26, 2024 / RedChip Companies will air interviews with LOBO EV Technologies Ltd. (Nasdaq:LOBO) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 27, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

Access the interviews in their entirety at:

In an exclusive interview, Harry Schulman, an independent director of LOBO EV, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. LOBO EV, headquartered in Wuxi, China, is a pioneering OEM and ODM manufacturer and seller of electric vehicles (EVs), including e-bicycles, e-mopeds, e-tricycles, and electric off-highway four-wheeled shuttles, tailored for various demographics, including mobility solutions for the elderly and disabled. Beyond vehicle manufacturing, LOBO EV offers automobile information and entertainment software development services to industry OEMs. The Company has a proven track record of leveraging advanced technologies in connectivity, multimedia, interactive systems, and artificial intelligence to enhance user experience with affordable, convenient, and enjoyable driving solutions. The Chinese e-bike market, currently valued at $16 billion, is forecasted to nearly double, reaching $31.3 billion in the next five years with a compound annual growth rate (CAGR) of 11.76%, according to Research and Markets. LOBO EV's robust financial performance across its key segments, coupled with the vast market opportunities within China's EV industry, position LOBO EV for significant upside.

Mark White, CEO of Nexalin, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. Nexalin stands at the forefront of the mental health treatment revolution with its cutting-edge, non-invasive neurostimulation technology. By focusing on deep brain stimulation, Nexalin's devices, particularly the advanced Gen-3 HALO™ Clarity, offer a groundbreaking alternative to traditional pharmacological treatments. This technology has shown clinically meaningful improvements in treating conditions such as insomnia, PTSD, and traumatic brain injuries - conditions that affect millions but have limited effective treatments - positioning Nexalin as an emerging leader in a market poised for substantial growth, projected to reach $537 billion by 2030.